Integra LifeSciences Appoints Mojdeh Poul President and CEO

Integra LifeSciences Holdings Corporation’s board of directors has appointed Mojdeh Poul as the new president and chief executive officer, effective January 6, 2025. She will also join the Integra board when she assumes the role. 

Poul will succeed Jan De Witte, who will remain president and CEO until January 6, 2025. Stuart Essig will remain executive chairman of Integra for a limited time before returning to his prior role as non-executive chairman.

“I want to express my sincerest gratitude to our dedicated and talented Integra colleagues for their resilience and determination over the years and their unwavering commitment to our mission to help customers and patients,” said De Witte. “Integra has been a pioneer in medical innovations for 35 years and I believe its portfolio of technological advancements and its people, whose passion and commitment to our purpose and values, are instrumental to Integra’s success, now and well into the future.”

“The board and I are thrilled to welcome Mojdeh as Integra’s next president and CEO,” said Stuart Essig, executive chairman of Integra. “Mojdeh is a seasoned global healthcare executive who brings a wealth of knowledge and expertise in business strategy and transformation, commercial excellence, and leadership development. Her passion for building high-performance teams that navigate complexity and deliver results will be critical in driving and successfully executing our strategic and operational plans. Mojdeh’s proven track record in advancing the vision and leadership impact of the companies she has served gives me great confidence she will successfully lead Integra in its mission to set new standards of care.”

Poul most recently served as vice president and group president of 3M’s Global Helathcare Business. At 3M, she oversaw R&D, manufacturing and commercial operations, quality, and regulatory functions. Poul and her team led the transformation of the healthcare portfolio through several strategic acquisitions and divestitures. 

Before 3M, Poul held global business leadership positions of increasing responsibility at Medtronic and Boston Scientific. In these roles, she accelerated neuromodulation and emerging cardiovascular technologies and therapies through the deployment of multifaceted market development strategies.

“I am honored to serve as the next president and CEO of Integra and thankful to Stuart and the board for their trust in my leadership,” Poul commented. “As we work through the transition, we will remain sharply focused on executing our operational and quality compliance strategic priorities, while maximizing the potential of Integra’s leading product portfolio. I look forward to partnering with the board and working with our teams and customers to advance our products and technologies to restore patients’ lives.”